Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Moby

Strategic Execution and Market Dynamics

Revenue more than doubled year-over-year, driven by the strategic pivot to prioritize high-frequency engagement with gastroenterologists (GIs) over primary care. Management identifies New-to-Brand (NBRx) market share as the primary leading indicator for future growth, noting that top 300 GI writers select VOQUEZNA for nearly 1 out of every 2 therapy switches. The sales force expansion to 290 representatives is now complete, enabling deeper penetration into the approximately 20 million annual PPI prescriptions written by GIs. Performance attribution for the quarter includes expected seasonality and winter storm impacts, though late March and April trends indicate a return to growth trajectory. Strategic positioning focuses on building a $1 billion GI business first, with a secondary $1 billion primary care opportunity expected to develop organically as patients cycle back to their PCPs. Patient persistence data shows high adherence, with 2024 cohorts averaging six bottles dispensed annually and an additional 18% of patients restarting therapy after a gap. Management views the potential 2027 entry of a second P-CAB as a category-building event that will increase physician awareness without disrupting VOQUEZNA's established clinical confidence.

2026 Outlook and Strategic Milestones

Reiterated 2026 net revenue guidance of $320 million to $345 million, with performance expected to be more heavily weighted toward the second half of the year. Anticipate achieving non-GAAP operating profitability by Q3 2026 and full-year 2026, with positive cash flow projected for 2027. The Phase II EoE trial is enrolling ahead of schedule, with top-line data now expected between late Q4 2026 and early Q1 2027. Cash operating expenses are expected to step up modestly in Q2 to reflect a full quarter of the expanded sales force and accelerated R&D spending. Current cash reserves and projected operational cash flow are deemed sufficient to satisfy all debt obligations and growth investments without further equity or debt raises.

Operational Context and Risk Factors

Gross-to-net (GTN) discounts for Q1 were at the lower end of the 55% to 59% range, primarily due to a higher mix of cash-pay prescriptions during the annual insurance reset period. The IQVIA reporting gap previously identified was fully resolved by mid-March, and reported TRx figures now include previously uncaptured prescriptions. A shift in accounting now reflects certain third-party fulfillment costs within cost of goods sold rather than as GTN adjustments, maintaining a gross margin of approximately 80%. Management is actively evaluating complementary GI assets for potential M&A to leverage the existing sales infrastructure, though no transactions are imminent.

Story Continues

Q&A Session Highlights

Competitive dynamics and differentiation against upcoming P-CAB entrants

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management emphasized that VOQUEZNA's 93% healing rate in Phase III trials provides a high clinical bar that is unlikely to be disrupted by cross-trial statistical comparisons. The entry of a second player is expected to shift the narrative from 'new product' to 'new category,' potentially accelerating the transition away from legacy PPIs.

Sustainability of gross-to-net yield and channel mix

The Q1 GTN favorability was attributed to a seasonal spike in cash-pay scripts as patients navigated high-deductible plan resets; this is expected to normalize within the 55% to 59% range for the full year.

Expansion into Eosinophilic Esophagitis (EoE) and other indications

Rapid enrollment in the EoE trial suggests significant unmet demand for first-line acid suppression therapies that avoid the burden of more aggressive immunologic treatments. Management is exploring additional opportunities including 'as-needed' dosing and addressing GERD symptoms associated with GLP-1 weight-loss therapies.

Recapture of primary care market through GI referrals

Early data shows primary care physicians (PCPs) are beginning to write VOQUEZNA prescriptions without direct sales calls, driven by patients returning from specialists with positive feedback. This organic 'halo effect' is viewed as the foundation for a future formal re-entry into the primary care segment.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

View Comments